<DOC>
	<DOCNO>NCT01738451</DOCNO>
	<brief_summary>This Phase I , multicenter , 2-part study Part 1 design safety lead-in Part 2 design evaluate effect GSK2118436 cardiac repolarization ( correct QT interval [ QTc ] duration ) compare placebo subject V600 BRAF mutation-positive tumor . Each part study consist screening ( 14 day prior start study treatment ) , treatment follow-up period ( 14 day ) . In Part 1 Cohort 1 six subject receive GSK2118436 225 mg twice day ( BID ) study day 1 7 single 225 milligram ( mg ) dose morning Day 8 . Based safety data subject Cohort 1 subject enrol Cohort 2 dose GSK2118436 escalate 300 mg BID . If 225 mg dose GSK2118436 well tolerate Cohort 1 ( i.e. , 2 dose-limiting toxicity [ DLTs ] ) , Cohort 2 Part 1 initiate dose 150 mg BID GSK2118436 administer Part 2 study . In Cohort 2 six subject receive GSK2118436 300 mg BID Study Days 1 7 single 300 mg dose morning Day 8 . Based safety data subject Cohort 2 subject enrol Part 2 . If 300 mg BID dose level GSK2118436 well tolerate , high tolerate dose select Part 2 study . In Part 1 study decision proceed next cohort Part 2 study base safety data least 6 evaluable subject ( &lt; =1 DLTs 14 day follow first dose GSK2118436 ) . In Part 2 study eligible subject receive single dose GSK2118436/placebo ( 4 capsule 75 mg/highest tolerate dose ) orally first 2 day study follow 2 dos daily 6 day single dose 9th day . There 1 day placebo give . In part study serial blood sample pharmacokinetic ( PK ) analysis GSK2118436 metabolites ( GSK2285403 , GSK2298683 GSK2167542 ) obtain time point first last day dose ( 2nd day dose also include Part 2 ) . Safety electrocardiogram ( ECG ) perform several timepoints study . In Part 2 Holter ECG monitoring perform 24 hour 1st , 2nd 9th day dose .</brief_summary>
	<brief_title>A Study Evaluate Effect Repeat Oral Dosing GSK2118436 Cardiac Repolarization Subjects With V600 BRAF Mutation-Positive Tumors</brief_title>
	<detailed_description />
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Has provide sign , write informed consent study . Male female , age &gt; =18 year age time sign informed consent form Has confirm diagnosis V600 BRAFmutation positive tumor determine appropriate genetic testing . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Has adequate baseline organ function define : Absolute neutrophil count &gt; =1.2 × 10^9/liter ( L ) , hemoglobin &gt; =9 gram ( g ) /deciliter ( dL ) , platelets &gt; = 75 × 10^9/L , prothrombin time ( PT ) , international normalization ratio ( INR ) partial thromboplastin time ( PTT ) &lt; =1.3 time upper limit normal ( ULN ) , total bilirubin &lt; =1.5 time ULN , alanine aminotransferase ( ALT ) &lt; =2.5 time ULN ; &lt; 5 time ULN liver metastasis present , creatinine &lt; =1.5 time ULN , calculate creatinine clearance 24hour urine creatinine clearance &gt; =60 mL/min leave ventricular ejection fraction ( LVEF ) &gt; = institutional low limit normal ( LLN ) echocardiogram ( ECHO ) . For Part 2 subject : Have serum potassium , serum magnesium , total serum calcium level within normal limit . Able swallow retain orally administer medication clinically significant GI abnormality may alter absorption malabsorption syndrome major resection stomach bowel . If female subject childbearing potential , must negative serum pregnancy test within 14 day first dose study treatment agree use effective contraception , study 4 week follow last dose study treatment . Known immediate delay hypersensitivity reaction dabrafenib excipients ; Any follow ECG finding : QT duration correct use Fridericia 's formula ( QTcF ) interval &gt; 450 millisecond ( msec ) , PR interval &gt; 220 msec &lt; =110 msec , bradycardia define sinus rate &lt; 50 beat per minute ( bpm ) Cardiac conduction abnormality denote follow : evidence seconddegree ( type II ) thirddegree atrioventricular block , evidence ventricular preexcitation , electrocardiographic evidence complete leave bundle branch block ( LBBB ) , intraventricular conduction delay QRS duration &gt; 120 msec , evidence atrial fibrillation history atrial fibrillation within past 6 month presence cardiac pacemaker History one follow cardiovascular condition within past 6 month : Class II , III , IV heart failure define New York Heart Association ( NYHA ) , cardiac angioplasty stenting , myocardial infarction , unstable angina symptomatic peripheral vascular disease clinically significant cardiac disease LVEF , measure ECHO , institutional LLN , LLN exist institution , &lt; 50 % . Abnormal cardiac valve morphology ( &gt; =grade 2 ) document echocardiogram ( subject minimal abnormality [ ie , mild regurgitation/stenosis ] enter ) Moderate valvular thicken Personal immediate family history longQT syndrome . Anticancer therapy ( e.g. , chemotherapy delay toxicity , extensive radiation therapy , immunotherapy , biologic therapy , major surgery ) within 21 day prior enrolment ; chemotherapy regimens without delayed toxicity within 14 day prior enrollment ; use investigational anticancer drug within 28 day precede first dose study treatment . Current use prohibit medication ( ) require medication treatment study treatment Current use therapeutic warfarin . Unresolved toxicity Grade 2 high previous anticancer therapy , except alopecia hemoglobin . A history know Human Immunodeficiency Virus , Hepatitis B Virus ( HBV ) , Hepatitis C Virus infection . Subjects document laboratory evidence HBV clearance may enrol . A history know glucose6phosphate dehydrogenase ( G6PD ) deficiency . Brain metastasis : symptomatic , treat ( surgery , radiation therapy ) clinically radiographically stable 1 month local therapy , asymptomatic untreated &gt; 1 centimeter ( cm ) long dimension Uncontrolled medical condition ( i.e. , diabetes mellitus , hypertension ) , psychological , familial , sociological , geographical condition permit compliance protocol ; unwillingness inability follow procedure require protocol . History another malignancy ; Only ( ) Subjects successfully treat diseasefree 3 year , ( b ) history completely resect nonmelanoma skin cancer , ( c ) successfully treat situ carcinoma , ( ) CLL stable remission , ( e ) indolent prostate cancer ( definition : clinical stage T1 T2a , Gleason score &lt; =6 , PSA &lt; 10 nanogram ( ng ) /mL ) require antihormonal therapy histologically confirm tumour lesion clearly differentiate lung cancer target nontarget lesion eligible Pregnant lactating/actively breastfeed female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Holter monitor</keyword>
	<keyword>cancer</keyword>
	<keyword>BRAF inhibitor</keyword>
	<keyword>BRAF-mutation positive tumor</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>QTc</keyword>
	<keyword>ECG interval morphology</keyword>
	<keyword>GSK2118436</keyword>
	<keyword>safety</keyword>
</DOC>